US1421521071
US1421521071
Caris Life Sciences, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 8.39B EUR | 5.04B EUR | 5.05B EUR | 7.62B EUR |
Enterprise Value | 7.43B EUR | 4.8B EUR | 4.66B EUR | 7.25B EUR |
Valuation Multiples | ||||
Trailing P/E | 17.57x | 47.9x | 148.72x | 220.99x |
Forward P/E | 80.46x | -- | -- | -- |
Price to Sales | 8.48x | 5.09x | 5.57x | 11.03x |
Price to Book | 14.18x | 8.51x | 8.52x | 13.2x |
EV/Revenue | 7.51x | 4.85x | 5.14x | 10.5x |
EV/EBITDA | 42.7x | 23.75x | 30.84x | 54.14x |
Price to FCF (P/FCF) | 132.67x | 40.62x | 40.94x | 75.53x |
EV/FCF | 117.46x | 38.7x | 37.78x | 71.88x |
FCF Yield | 0.75% | 2.46% | 2.44% | 1.32% |